Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hemoglobin levels and 30-day mortality in patients after myocardial infarction.
Lipsic E, van der Horst IC, Voors AA, van der Meer P, Nijsten MW, van Gilst WH, van Veldhuisen DJ, Zijlstra F. Lipsic E, et al. Among authors: van gilst wh, van der horst ic, van der meer p, van veldhuisen dj. Int J Cardiol. 2005 Apr 20;100(2):289-92. doi: 10.1016/j.ijcard.2004.10.043. Int J Cardiol. 2005. PMID: 15823637
Anemia and congestive heart failure.
van der Meer P, van Gilst WH, van Veldhuisen DJ. van der Meer P, et al. Among authors: van gilst wh, van veldhuisen dj. Circulation. 2003 Aug 12;108(6):e41-2; author reply e41-2. Circulation. 2003. PMID: 12914016 No abstract available.
Erythropoietin in cardiovascular diseases.
van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. van der Meer P, et al. Among authors: van gilst wh, van veldhuisen dj. Eur Heart J. 2004 Feb;25(4):285-91. doi: 10.1016/j.ehj.2003.11.017. Eur Heart J. 2004. PMID: 14984916 Review.
Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion.
Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Lipsic E, et al. Among authors: van gilst wh, van der meer p, van veldhuisen dj. J Cardiovasc Pharmacol. 2004 Oct;44(4):473-9. doi: 10.1097/01.fjc.0000140209.04675.c3. J Cardiovasc Pharmacol. 2004. PMID: 15454856
Erythropoietin: from hematopoiesis to cardioprotection.
van der Meer P, Lipsic E, van Gilst WH, van Veldhuisen DJ. van der Meer P, et al. Among authors: van gilst wh, van veldhuisen dj. Cardiovasc Drugs Ther. 2005 Jan;19(1):7-8. doi: 10.1007/s10557-005-6891-5. Cardiovasc Drugs Ther. 2005. PMID: 15883750 No abstract available.
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. van der Meer P, et al. Among authors: van gilst wh, van der velden j, van veldhuisen dj. J Am Coll Cardiol. 2005 Jul 5;46(1):125-33. doi: 10.1016/j.jacc.2005.03.044. J Am Coll Cardiol. 2005. PMID: 15992646 Free article.
Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure.
van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH. van der Meer P, et al. Among authors: van de wal rm, van gilst wh, van veldhuisen dj. Circulation. 2005 Sep 20;112(12):1743-7. doi: 10.1161/CIRCULATIONAHA.105.549121. Circulation. 2005. PMID: 16172283
640 results